Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112

References

• WilliamsHDTrevaskisNLCharmanSAStrategies to address low drug solubility in discovery and developmentPharmacol Rev201365131549923383426
   PubMed Web of Science ®Google Scholar
• MattheolabakisGRigasBConstantinidesPPNanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectivesNanomedicine (Lond)20127101577159023148540
   PubMed Web of Science ®Google Scholar
• LiuXLLynnBCZhangJHA versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugsJ Am Chem Soc2002124267650765112083906
   PubMedGoogle Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Del Rev20136513648
   PubMed Web of Science ®Google Scholar
• GuptaSBiocompatible microemulsion systems for drug encapsulation and deliveryCurr Sci20111012174188
   Google Scholar
• ZhangXJZhangXGYuPEHanYLiYLiCHydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery systemJ Pharm Sci2013102114515323132353
   PubMed Web of Science ®Google Scholar
• LuYParkKPolymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugsInt J Pharm2013453119821422944304
   PubMed Web of Science ®Google Scholar
• QiJLuYWuWAbsorption, disposition and pharmacokinetics of solid lipid nanoparticlesCurr Drug Metab201213441842822443536
   PubMed Web of Science ®Google Scholar
• XuSOlenyukBZOkamotoCTHamm-AlvarezSFTargeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advancesAdv Drug Del Rev2013651121138
   Google Scholar
• MöschwitzerJPDrug nanocrystals in the commercial pharmaceutical development processInt J Pharm2013453114215623000841
   PubMed Web of Science ®Google Scholar
• CarterNJExtended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophreniaDrugs20127281137116022571444
   PubMed Web of Science ®Google Scholar
• BöhmBHMüllerRHLab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugsPharm Sci Technolo Today19992833633910441278
   PubMedGoogle Scholar
• RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov20043978579615340388
   PubMed Web of Science ®Google Scholar
• SudhakarBNagaJyothiKMurthyKVNanosuspensions as a versatile carrier based drug delivery system – an overviewCurr Drug Deliv201411329930524655052
   PubMedGoogle Scholar
• KesisoglouFPanmaiSWuYNanosizing – oral formulation development and biopharmaceutical evaluationAdv Drug Deliv Rev200759763164417601629
   PubMed Web of Science ®Google Scholar
• MüllerRHJacobsCBuparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stabilityInt J Pharm20022371–215116111955813
   PubMed Web of Science ®Google Scholar
• PignatelloRRicuperoNBucoloCMaugeriFMalteseAPuglisiGPreparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromeneAAPS Pharm Sci Tech2006241E27
   Google Scholar
• XiongRLuWYuePDistribution of an intravenous injectable nimodipine nanosuspension in miceJ Pharm Pharmacol20086091155115918718118
   PubMedGoogle Scholar
• AndesDIn vivo pharmacodynamics of antifungal drugs in treatment of candidiasisAntimicrob Agents Chemother20034741179118612654644
   PubMedGoogle Scholar
• GantaSPaxtonJWBaguleyBCGargSFormulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous deliveryInt J Pharm20093671–217918618848873
   PubMed Web of Science ®Google Scholar
• HollisCP1WeissHLLeggasMEversBMGemeinhartRALiTBiodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug deliveryJ Control Release20031721122123920039
   PubMedGoogle Scholar
• AliHSYorkPBlagdenNPreparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactorsInt J Pharm20093751–210711319481696
   PubMed Web of Science ®Google Scholar
• KeckCMMüllerRHDrug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEur J Pharm Biopharm200662131616129588
   PubMed Web of Science ®Google Scholar
• Van EerdenbrughBVan den MooterGAugustijnsPTop-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid productsInt J Pharm20083641647518721869
   PubMed Web of Science ®Google Scholar
• ChenHWanJWangYA facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactionsNanotechnology2008193737510421832541
   PubMed Web of Science ®Google Scholar
• GaoLLiuGWangXLiuFXuYMaJPreparation of a chemically stable quercetin formulation using nanosuspension technologyInt J Pharm20114041–223123721093559
   PubMed Web of Science ®Google Scholar
• XiaDGanYCuiFApplication of precipitation methods for the production of water-insoluble drug nanocrystals: production techniques and stability of nanocrystalsCurr Pharm Des201420340843523651396
   PubMed Web of Science ®Google Scholar
• MüllerRHGohlaSKeckCMState of the art of nanocrystals – special features, production, nanotoxicology aspects and intracellular deliveryEur J Pharm Biopharm20117811921266197
   PubMed Web of Science ®Google Scholar
• ChandarlapatySSawaiAYeQSNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancersClin Cancer Res200814124024818172276
   PubMedGoogle Scholar
• OkawaYHideshimaTSteedPSNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKBlood2009113484685518948577
   PubMed Web of Science ®Google Scholar
• LiuHSunHWuZZhangXWuBP-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in ratsXenobiotica201444876376824555822
   PubMed Web of Science ®Google Scholar
• RowlandMPeckCTuckerGPhysiologically-based pharmacokinetics in drug development and regulatory scienceAnnu Rev Pharmacol Toxicol201151457320854171
   PubMed Web of Science ®Google Scholar
• AtkinsonAJJrSmithBPModels of physiology and physiologically based models in clinical pharmacologyClin Pharmacol Ther20129213622713729
   PubMedGoogle Scholar
• ChowECPangKSWhy we need proper PBPK models to examine intestine and liver oral drug absorptionCurr Drug Metab2013141577922935069
   PubMedGoogle Scholar
• PangKSDurkMRPhysiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretionJ Pharmacokinet Pharmacodyn201037659161521153869
   PubMedGoogle Scholar
• Rostami-HodjeganAPhysiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacologyClin Pharmacol Ther2012921506122644330
   PubMed Web of Science ®Google Scholar
• KaganLGershkovichPWasanKMMagerDEDual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B dispositionPharm Res2014311354523793994
   PubMed Web of Science ®Google Scholar
• BartaTEVealJMRiceJWDiscovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90Bioorg Med Chem Lett200818123517352118511277
   PubMedGoogle Scholar
• TuomelaALiuPPuranenJBrinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivoInt J Pharm20144671–2344124680962
   PubMed Web of Science ®Google Scholar
• LevyMYBenitaSDrug release from submicronized o/w emulsion: a new in vitro kinetic evaluation modelInt J Pharm1990661–32937
   Web of Science ®Google Scholar
• LiuHSunHLuDIdentification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidenceXenobiotica201444869670724555821
   PubMed Web of Science ®Google Scholar
• LiuWLiuHSunHMetabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)Xenobiotica201444545546424191862
   PubMed Web of Science ®Google Scholar
• KaganLGershkovichPWasanKMMagerDEPhysiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published dataAAPS J201113225526421431453
   PubMedGoogle Scholar
• WongJBruggerAKhareASuspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspectsAdv Drug Deliv Rev200860893995418343527
   PubMed Web of Science ®Google Scholar
• HonarySZahirFEffect of zeta potential on the properties of nano-drug delivery systems – a review (part 2)Trop J Pharm Res2013122265273
   Google Scholar
• KenthSSylvestreJPFuhrmannKMeunierMLerouxJCFabrication of paclitaxel nanocrystals by femtosecond laser ablation and fragmentationJ Pharm Sci201110031022103020809524
   PubMedGoogle Scholar
• LiYSunSChangQA strategy for the improvement of the bioavailability and antiosteoporosis activity of BCS IV flavonoid glycosides through the formulation of their lipophilic aglycone into nanocrystalsMol Pharm20131072534254223659498
   PubMedGoogle Scholar
• ChowECDurkMRCumminsCLPangKS1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(−/−) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivoJ Pharmacol Exp Ther2011337384685921421739
   PubMed Web of Science ®Google Scholar
• GaoLZhangDChenMStudies on pharmacokinetics and tissue distribution of oridonin nanosuspensionsInt J Pharm20083551–232132718242896
   PubMed Web of Science ®Google Scholar
• RabinowBKippJPapadopoulosPItraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the ratInt J Pharm20073391–225126017398045
   PubMed Web of Science ®Google Scholar
• LiuYHuangLLiuFPaclitaxel nanocrystals for overcoming multidrug resistance in cancerMol Pharm20107386386920420443
   PubMedGoogle Scholar
• ZhangHHollisCPZhangQLiTPreparation and antitumor study of camptothecin nanocrystalsInt J Pharm20114151–229330021679755
   PubMedGoogle Scholar
• SongHGengHQRuanJDevelopment of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal modelsNanoscale Res Lett20116135421711889
   PubMedGoogle Scholar
• MoutonJWvan PeerAde BeuleKVan VlietADonnellyJPSoonsPAPharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulationAntimicrob Agents Chemother200650124096410216982783
   PubMed Web of Science ®Google Scholar